Perspective: Combined forces

Charles L. Sawyers
Additional contact information
Charles L. Sawyers: Charles L. Sawyers is chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan-Kettering Cancer Center in New York and a Howard Hughes Medical Institute investigator. He is also a co-inventor of patents covering imatinib-resistant BCR–ABL mutations and serves on the board of directors of Novartis Pharmaceuticals. Novartis provided an unrestricted educational grant to support the production of this supplement. Novartis had no editorial input into the content of this article.

Nature, 2013, vol. 498, issue 7455, S7-S7

Abstract: Beginning treatment with a combination of drugs should help to stop drug resistance developing, says Charles L. Sawyers.

Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/498S7a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:498:y:2013:i:7455:d:10.1038_498s7a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/498S7a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().